Pharmaceutical

Amgen results for Kyprolis could sideline Velcade

Amgen results for Kyprolis could sideline Velcade

By

Analysts say head-to-head study results could make Kyprolis the lead treatment.

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

By

Drugmakers face increasing pressure on pricing from insurers and PBMs.

Pradaxa antidote goes to FDA

The breakthrough designation therapy drug was the first for its drug class.

GAO: Dementia patients receiving harmful antipsychotics

Researchers said 33% of Medicare Part D nursing home patients were receiving the drug for symptoms associated with dementia.

Five things for pharma marketers to know: Monday, March 2

Five things for pharma marketers to know: Monday, March 2

By

Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.

Five things for pharma marketers to know: Friday, February 27

Five things for pharma marketers to know: Friday, February 27

By

Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.

PCORI explains how it will release comparative-effectiveness findings

PCORI explains how it will release comparative-effectiveness findings

By

The organization plans to publish a scientific and a lay abstract detailing study findings

Drugmaker shifts sales model to keep pace with formulary decision making

Drugmaker shifts sales model to keep pace with formulary decision making

By

Some IDNs are centralizing decisionmaking at the corporate level and other hospitals are limiting on-site access to sales reps.

BI rare-disease awareness push slated for Saturday

Industry rare disease awareness efforts included a pipeline overview at Pfizer as well as BI's efforts to draw attention to IPF.

Lilly Lantus biosimilar to hit EU

The EU will have access to the new medication in May.

Five things for pharma marketers to know: Thursday, February 26

Five things for pharma marketers to know: Thursday, February 26

By

Sanofi's Lantus predecessor nabs approval; Pharmacyclics reportedly vets acquisition offers; FDA biosimilar hearing is postponed.

Poll shows all ages seek digital health tools

Poll shows all ages seek digital health tools

By

Millennials and baby boomers have a lot of common: a desire for technology that supports health priorities.

GSK re-launches OTC diet pill

The over-the-counter weight-loss drug Alli saw a return to drugstores this week after a year hiatus.

Five things for pharma marketers to know: Wednesday, February 25

Five things for pharma marketers to know: Wednesday, February 25

By

J&J loses another Risperdal case; Pfizer slashes jobs at research center; Actavis challenges ulcerative colitis drug's patent.

Global cancer drug market to grow to $111 billion by 2020: report

Global cancer drug market to grow to $111 billion by 2020: report

By

The global cancer market is expected to reach $111 billion by 2020, according to new market research, with immunotherapies—particularly in lung cancer—expected to drive growth.

UK doctors lobby for off-label Avastin use

Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.

California ponders drug pricing reveal

Assemblyman David Chiu's bill would publish a drug's R&D and related costs.

Five things for pharma marketers to know: Tuesday, February 24

Five things for pharma marketers to know: Tuesday, February 24

By

FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.

Survey shows docs shrug off Sunshine

A MedPanel survey indicates doctors have not changed their business practices since the Open Payments database went live.

Five things for pharma marketers to know: Friday, February 20

Five things for pharma marketers to know: Friday, February 20

By

23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.

Poll highlights cholesterol knowledge gap

Poll highlights cholesterol knowledge gap

By

Americans may be taking anti-cholesterol medications, but it doesn't mean they are aware of their impact.

McNeil consumer president named HBA Woman of the Year

The Healthcare Businesswomen's Association named Denice Torres, president of J&J's McNeil Consumer Healthcare, as its 26th Woman of the Year.

Five things for pharma marketers to know: Thursday, February 19

Five things for pharma marketers to know: Thursday, February 19

By By

Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for "drug reaction reviews"; Roche skin-cancer drug receives Priority Review.

Five things for pharma marketers to know: Wednesday, February 18

Five things for pharma marketers to know: Wednesday, February 18

By

Researchers find repeat marketing offenders in the UK and Sweden, Actavis plans to take Allergan's name and Sanofi enters an auto-immune disease collaboration.

Survey shows docs overestimate adherence

Survey shows docs overestimate adherence

By

A small physician survey shows doctors think their patients have higher adherence rates than the norm.

Specialty medications have PBMs on edge

Specialty medications have PBMs on edge

By

CVS health execs write that cost of long-term specialty medications, not short-timers like Sovaldi, are a major worry.

Court invalidates patent for AstraZeneca asthma drug

A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.

Five things for pharma marketers to know: Tuesday, February 17

Five things for pharma marketers to know: Tuesday, February 17

By

Bayer exec may be Sanofi's new CEO, GSK gets a new North American Pharma lead, and Pfizer sends painkiller ALO-02 to the FDA.

Pfizer teams up with Alzheimer's foundation

Pfizer's academic research arm will work together with the Alzheimer's Drug Discovery Foundation to jointly invest in scientific research to identify clinical candidates for testing.

Sanofi lays off 100 at Boston R&D hub

The Paris-based drugmaker has axed 100 oncology and global R&D employees as part of a reorganization effort.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters